- Home
- FROG vs AXSM Comparison
FROG vs AXSM Comparison
Compare FROG & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FROG | AXSM |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 9.0B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FROG | AXSM |
|---|---|---|
| Price | $41.55 | $154.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 17 |
| Target Price | $66.84 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 4.3M | 493.1K |
| Earning Date | 05-14-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.59 | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $531,840,000.00 | N/A |
| Revenue This Year | $20.21 | $58.34 |
| Revenue Next Year | $16.87 | $54.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.12 | N/A |
| 52 Week Low | $27.00 | $86.99 |
| 52 Week High | $70.43 | $191.50 |
Technical Indicators
Market Signals| Indicator | FROG | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 30.40 |
| Support Level | $41.63 | $148.14 |
| Resistance Level | $45.01 | $191.13 |
| Average True Range (ATR) | 2.50 | 5.49 |
| MACD | 0.67 | -1.32 |
| Stochastic Oscillator | 83.85 | 6.36 |
Price Performance
Historical ComparisonAbout FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from united states and also has its presence in Israel, India and other regions.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.